TBXT and type 1 diabetes mellitus: In 2022, the US Food and Drug Administration (FDA) approved teplizumab, a humanised immunoglobulin G1 antibody that binds the T cell receptor CD3ε chain, to delay onset of stage 3 type 1 diabetes in individuals aged ≥8 years with stage 2 type 1 diabetes [21].